Abstract 154P
Background
The variants of urothelial carcinoma such as micropapillary (MP), plasmacytoid (PC), and lipid cell (LC) carry a very poor prognosis. High progression speed and resistance to chemotherapy are considered to be part of the reasons for poor prognosis. Accordingly, early diagnosis and early treatment are important to improve prognosis. In this study, we elucidated the cytological diagnostic criteria of these variants, and also investigated whether preoperative urine cytology could diagnose these variants and the possible association between cytological predictability and pathological features.
Methods
Between April 2015 and March 2020, 45 patients were histologically diagnosed as MP, PC, and LP by TURBT in our institution. The experienced cytologists (YW) in our hospital re-evaluated the preoperative urine cytology in these cases to determine whether or not the prediction of the variant histology is possible. The following findings were used as criteria, small papillary cell clumps with strong binding in MP, circular atypical cells similar to plasma cells in PC, and atypical cells similar to lipoblasts with empty cells in LC. Additionally, we analyzed whether histopathological findings such as muscle invasion, tumor size, tumor necrosis, lymphovascular invasion (LVI), CIS, affect the prediction of the variants.
Results
Of 45 cases, MP, PC and LC were 18 (40%), 13 (29%) and 14 (31%) patients, respectively. 3 cases of MP (17%), 5 of PC (38%) and 2 of LC (14%) could be predicted by re-evaluating preoperative urine cytology. In addition, positive preoperative urine cytology (class 4 or higher) was found in 14 cases in MP (78%), 8 cases in PC (62%), and 11 cases in LC (79%), with estimated probabilities of 21%, 62%, and 18%, respectively. Pathological features were not different between the predictable and unpredictable cases: muscle invasion, 90% vs 74% (P = 0.26); median tumor size, 31 mm vs 38 mm (P = 0.37); tumor necrosis, 20% vs 28% (P = 0.64); LVI, 60% vs 45% (P = 0.42); CIS, 40% vs 34% (P = 0.74), respectively.
Conclusions
Although in some cases, atypical cells suggesting UC variants appeared in the urine cytology, this study suggested that the preoperative cytological diagnosis of bladder cancer variants seems to be difficult.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03
186P - Degradation of BRCA2 expression by hyperthermia sensitizes HRD-negative (BRCA2 wild-type) ovarian cancer cells to niraparib
Presenter: Junyang Li
Session: Poster viewing 03